Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009390 | 0.87 | GPR119 (0.44) | KDM4EMAPTTHRBGPR119HPGD | |
| SCHEMBL18166161 | 0.85 | MAPT (0.40) | KDM4EMAPTTHRBGPR119STS | |
| SCHEMBL16698699 | 0.79 | GPR119 (0.42) | MBOAT4KDM4EMAPTTHRBGPR119 | |
| SCHEMBL19991495 | 0.76 | MBOAT4 (0.65) | MBOAT4KDM4EGPR119 | |
| SCHEMBL16049455 | 0.73 | MAP4K4 (0.44) | KDM4EMAPTTHRBGPR119STS | |
| SCHEMBL25258371 | 0.72 | GPR119 (0.44) | MAPTGPR119STSMEN1KMT2A | |
| SCHEMBL29774310 | 0.72 | GPR119 (0.44) | KDM4EMAPTTHRBGPR119 | |
| SCHEMBL20839829 | 0.72 | GPR119 (0.44) | KDM4EMAPTTHRBGPR119 | |
| SCHEMBL30381534 | 0.72 | HPGD (0.49) | KDM4EMAPTTHRBGPR119STS | |
| SCHEMBL22776493 | 0.72 | GPR119 (0.45) | KDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428723-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-3283473-B1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | LILLY CO ELI (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-3283473-B1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | LILLY CO ELI (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10093651-B2 | Ghrelin O-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-29 | — | — | US | disclosed |
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-29 | — | — | US | disclosed |
| EP-3283473-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168222-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168222-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885KDM4E 961/4885MAPT 1378/4885 |
| US-10093651-B2 | Ghrelin O-acyl transferase inhibitors | MBOAT4, GIPR, DGAT1 | MBOAT4 1/4885KDM4E 926/4885MAPT 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.